Lifecore Biomedical, Inc. (LFCR)

Market Cap	237.15M
Revenue (ttm)	130.31M
Net Income (ttm)	-49.40M
Shares Out	37.03M
EPS (ttm)	-1.49
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	193,286
Open	6.35
Previous Close	6.34
Day's Range	6.29 - 6.54
52-Week Range	3.68 - 7.99
Beta	0.80
Analysts	Buy
Price Target	8.00 (+24.61%)
Earnings Date	Apr 3, 2025

About LFCR

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot stud...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1986
• Employees: 524
• Stock Exchange: NASDAQ
• Ticker Symbol: LFCR
• Website: https://www.lifecore.com

Analyst Forecast

According to 3 analysts, the average rating for LFCR stock is "Buy." The 12-month stock price forecast is $8.0, which is an increase of 24.61% from the latest price.

Price Target

$8.0

(24.61% upside)

Analyst Consensus: Buy